Gilles Salles is a Lymphoma Diagnosis and Treatment physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 1,727 publications with 80,377 citations (h-index 129); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Gilles Salles is affiliated with Memorial Sloan Kettering Cancer Center. The public record shows 1,727 publications with 80,377 citations (h-index 129), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 33 companies, 1 NIH-funded awards (2020–2020).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lymphoma Diagnosis and Treatment
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 33 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 111 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 675.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
- Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
Sponsor: The Lymphoma Academic Research Organisation
Industry payments
Updated 14 Oct 2026
33 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202517 payments$24,128openpaymentsdata.cms.gov ↗
- Hoffmann-La Roche LimitedProgram year20256 payments$21,116openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year20259 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
100%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor100%Acyclovir100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2020–2020 per NIH RePORTER. The latest:
- Development of Mechanism-Based Therapy For Myc+/Bcl2+ Diffuse Large B Cell Lymphoma
Sloan-Kettering Inst Can Research
FY2020$273,372P50CA192937
Congress activity
Updated 14 Oct 2026
319 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.
Journal of clinical oncology
Review2026
Most-cited works
by citation count (OpenAlex)- 01The 2016 revision of the World Health Organization classification of lymphoid neoplasmsArticle7,852 citations2016
- 02
- 03Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaArticle4,084 citations2018
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/gilles-salles-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/gilles-salles-02769386
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
synapse.mskcc.org/synapse/people/22478
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →synapse.mskcc.org ↗
Mentions by others
where others cite or feature them- Other
mskcc.org/cancer-care/doctors/gilles-salles
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Other
mskcc.org/news-releases/gilles-salles-named-chief-lymphoma-service
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Other
mskcc.org/videos/meet-gilles-salles-lymphoma-specialist-cellular-therapist-at-msk
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Seth Steinberg, PhD
National Cancer Institute (NCI)
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center
Anne Tsao, MD
The University of Texas MD Anderson Cancer Center